Helix BioMedix, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HXBM research report →
Companywww.helixbiomedix.com
Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections.
- CEO
- Robin L. Carmichael
- IPO
- 1999
- Employees
- 8
- HQ
- Bothell, WA, US
Price Chart
Valuation
- Market Cap
- $402.23K
- P/E
- -0.73
- P/S
- 0.50
- P/B
- 0.26
- EV/EBITDA
- 1.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.36%
- Op Margin
- -73.81%
- Net Margin
- -68.32%
- ROE
- -30.45%
- ROIC
- -38.72%
Growth & Income
- Revenue
- $807.19K · 0.37%
- Net Income
- $-551,512 · 43.86%
- EPS
- $-2.45 · 43.94%
- Op Income
- $-595,812
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $7.18
- 52W Low
- $1.00
- 50D MA
- $1.23
- 200D MA
- $2.70
- Beta
- 1.34
- Avg Volume
- 40
Get TickerSpark's AI analysis on HXBM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 26, 03 | BEATTY R STEPHEN | buy | 60,000 |
| Dec 26, 03 | BEATTY R STEPHEN | other | 25,000 |
| Dec 26, 03 | BEATTY R STEPHEN | other | 60,000 |
| Dec 26, 03 | BEATTY R STEPHEN | other | 25,000 |
Our HXBM Coverage
We haven't published any research on HXBM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HXBM Report →